The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

Description

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

Conditions

Neuropathic Pain, PTSD

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD: A Prospective Randomized Design

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

Condition
Neuropathic Pain
Intervention / Treatment

-

Contacts and Locations

San Antonio

Brooke Army Medical Center, San Antonio, Texas, United States, 78234

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-70 years old with Chronic Neuropathic Pain \>= 3 months
  • * Biologic male or biologic female
  • * Women of childbearing age will be included if there are no plans of pregnancy within the study period, the participant agrees to actively utilize contraception throughout the study, and agrees to pregnancy tests
  • * Active Duty, Veterans, and retirees
  • * Ketamine naïve for 1 year
  • * Moderate Neuropathic pain Scale 4-7
  • * Cognitive dysfunction
  • * Psychiatric illness involving psychosis
  • * Neurocognitive disorder
  • * Patients with Traumatic Brain Injury (TBI)
  • * Acute cardiovascular disease or poorly controlled hypertension
  • * Untreated or uncontrolled thyroid disease
  • * Hyperthyroidism
  • * Severe liver or renal disease
  • * Renal impairment
  • * History of recent heart attack, vascular disease, or any other medical condition that may be deemed by a provider as a contraindication to receiving ketamine
  • * Active substance abuse
  • * Pregnant or lactating
  • * Patients who are planning to become pregnant within 12 weeks of treatment completion
  • * Elevated Blood Pressure/hypertension
  • * Known hypersensitivity to Ketamine
  • * Hemodynamic instability
  • * Respiratory depression
  • * Use of Theophylline or Aminophylline, Sympathomimetics and Vasopressin,
  • * Use of Benzodiazepines
  • * A history of drug abuse or dependence
  • * Active risk of substance use
  • * Patients who are not able to abide by the pre-treatment and posttreatment clinical protocol, such as food intake, abstaining from certain medications, unable to remain in the clinic for a minimum of 1 hour for observation, and cannot provide the name and phone number of the party who will pick them up post-treatment

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Margaux M. Salas, PhD,

Study Record Dates

2027-05